Salud financiera de hoja de balance de Sinopharm Group
Salud financiera controles de criterios 5/6
Sinopharm Group tiene un patrimonio de accionistas total de CN¥122.4B y una deuda total de CN¥95.6B, lo que sitúa su ratio deuda-patrimonio en 78.1%. Sus activos y pasivos totales son CN¥429.6B y CN¥307.2B respectivamente. El BAIT de Sinopharm Group es de CN¥20.9B, por lo que su ratio de cobertura de intereses es de 11.4. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥43.3B.
Información clave
78.1%
Ratio deuda-patrimonio
CN¥95.61b
Deuda
| Ratio de cobertura de intereses | 11.4x |
| Efectivo | CN¥43.33b |
| Patrimonio | CN¥122.43b |
| Total pasivo | CN¥307.15b |
| Activos totales | CN¥429.58b |
Actualizaciones recientes sobre salud financiera
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Recent updates
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥382.4B) de 1099 superan a sus pasivos a corto plazo (CN¥283.2B).
Pasivo a largo plazo: Los activos a corto plazo de 1099 (CN¥382.4B) superan a sus pasivos a largo plazo (CN¥23.9B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de 1099 (42.7%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de 1099 ha pasado de 97.2% a 78.1% en los últimos 5 años.
Cobertura de la deuda: La deuda de 1099 está bien cubierta por el flujo de caja operativo (20.4%).
Cobertura de intereses: Los pagos de intereses de la deuda de 1099 están bien cubiertos por el BAIT (11.4x cobertura).